Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era

J Card Fail. 2022 Oct;28(10):1519-1521. doi: 10.1016/j.cardfail.2022.08.003. Epub 2022 Aug 18.

Authors

Raja Zaghlol¹, Molly Rater¹, Walter Schiffer¹, Joshua D Mitchell²

Affiliations

¹ Amyloid Center of Excellence, Cardiovascular Division, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
² Amyloid Center of Excellence, Cardiovascular Division, Washington University School of Medicine in St. Louis, St. Louis, Missouri. Electronic address: jdmitchell@wustl.edu.

PMID: 35988721
DOI: 10.1016/j.cardfail.2022.08.003

No abstract available

Publication types

Editorial
Comment

MeSH terms

Amyloid Neuropathies, Familial* / diagnosis
Amyloid Neuropathies, Familial* / drug therapy
Benzoxazoles
Cardiomyopathies* / diagnosis
Cardiomyopathies* / drug therapy
Heart Failure*
Humans
Prealbumin / genetics
Prognosis

Substances

Benzoxazoles
Prealbumin
tafamidis